Novartis-Pfizer trademark deal has opposite impact on their stock prices; Novartis India jumps 20% while Pfizer slips 3%
The two companies had announced on Monday that NIL had inked an agreement with Pfizer Inc to acquire the trademarks for India, besides certain related intellectual property rights, for ₹1,250 crore
Despite Novartis India Ltd's acquisition of Pfizer Inc's trademarks for 'Minipress' and 'Minipres' in India, the transaction has had contradictory effects on the respective stock prices of both companies. On Wednesday, the stock price of NIL rose by 20% to ₹2,188 on the BSE, driven by optimism surrounding the hypertension drug. Conversely, Pfizer's stock fell by 3.3% to ₹4,171.35 on the BSE.
The acquisition, valued at ₹1,250 crore, was finalized on Monday. The Systematix Group noted that Pfizer India would receive only ₹132 crore as the trademark ownership remained with the parent company. The divestment might impact Pfizer's net earnings, leading to an estimated decline in annual EBITDA by ₹60 crore. Meanwhile, NIL sees the Minipress acquisition as a means to expand its mass-market presence, leveraging its nephrologist connections for the Minipress XL franchise. The acquisition may become accretive to Novartis only in the second year.
Written by urgent.news from Hindu BusinessLine's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
